Cardiovascular and Renal Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark ; Department of Clinical Immunology, Region Sjaelland, Naestved Hospital, Naestved, Denmark ; Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.
PLoS One. 2013 Dec 4;8(12):e82383. doi: 10.1371/journal.pone.0082383. eCollection 2013.
Microfibrillar-associated protein 4 (MFAP4) is a systemic biomarker that is significantly elevated in samples from patients suffering from hepatic cirrhosis. The protein is generally localized to elastic fibers and other connective tissue fibers in the extracellular matrix (ECM), and variation in systemic MFAP4 (sMFAP4) has the potential to reflect diverse diseases with increased ECM turnover. Here, we aimed to validate an enzyme-linked immunosorbent assay (ELISA) for the measurement of sMFAP4 with an emphasis on the robustness of the assay. Moreover, we aimed to determine confounders influencing the basal sMFAP4 variability and the genetic contribution to the basal variation.
The sandwich ELISA was based on two monoclonal anti-MFAP4 antibodies and was optimized and calibrated with a standard of recombinant MFAP4. The importance of pre-analytical sample handling was evaluated regarding sample tube type, time, and temperature conditions. The mean value structure and variance structure was determined in a twin cohort including 1,417 Danish twins (age 18-67 years) by mixed-effect linear regression modeling.
The practical working range of the sandwich ELISA was estimated to be 4-75 U/ml. The maximum intra- and inter-assay variation was estimated to be 8.7% and 6.6%, respectively. Sample handling and processing appeared to influence MFAP4 measurements only marginally. The average concentration of sMFAP4 in the serum was 18.9 ± 8.4 (SD) U/ml in the twin cohort (95% CI: 18.5-19.4, median sMFAP4 17.3 U/ml). The mean structure model was demonstrated to include waist-hip ratio, age, and cigarette smoking status in interactions with gender. A relatively low heritability of h(2) = 0.24 was found after applying a model including additive genetic factors and shared and non-shared environmental factors.
The described ELISA provides robust measures of the liver fibrosis marker sMFAP4. The low heritability and the relatively limited basal variation suggest that increased sMFAP4 reflects disease-induced processes.
微纤维相关蛋白 4(MFAP4)是一种全身性生物标志物,在患有肝硬化的患者样本中显著升高。该蛋白通常定位于细胞外基质(ECM)中的弹性纤维和其他结缔组织纤维,全身性 MFAP4(sMFAP4)的变化有可能反映出具有较高 ECM 周转率的各种疾病。在这里,我们旨在验证用于测量 sMFAP4 的酶联免疫吸附测定(ELISA),重点是该测定的稳健性。此外,我们旨在确定影响基础 sMFAP4 变异性的混杂因素以及对基础变异的遗传贡献。
夹心 ELISA 基于两种抗 MFAP4 单克隆抗体,并用重组 MFAP4 标准品进行优化和校准。评估了样本管类型、时间和温度条件等样本前处理对样品处理的重要性。通过混合效应线性回归建模,在包括 1417 对丹麦双胞胎(年龄 18-67 岁)的双胞胎队列中确定平均值结构和方差结构。
夹心 ELISA 的实际工作范围估计为 4-75 U/ml。最大的内和间测定变异估计分别为 8.7%和 6.6%。样本处理和处理似乎仅对 MFAP4 测量有轻微影响。在双胞胎队列中,血清中 sMFAP4 的平均浓度为 18.9 ± 8.4(SD)U/ml(95%CI:18.5-19.4,中位数 sMFAP4 为 17.3 U/ml)。均值结构模型表明,性别与腰围-臀围比、年龄和吸烟状态存在相互作用。在包括加性遗传因素以及共享和非共享环境因素的模型中,发现相对较低的遗传度 h(2)= 0.24。
所描述的 ELISA 提供了肝脏纤维化标志物 sMFAP4 的可靠测量。遗传度较低且基础变异性相对有限表明,sMFAP4 的增加反映了疾病诱导的过程。